Cancer Investigation · 2009 · 20 citations · 20 references
MedicineMolecular BiologyOncologyMolecular OncologyNeoplasiaOncogenesCancer Molecular PathologyMalignant NeoplasmsMolecular Tumor ProfilingSquamous Cell CarcinomaTumor MarkersHer2 AmplificationHer2 ExpressionHer2 Gene AmplificationHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionPoint Mutation AnalysisSingle-strand Conformation Polymorphism
We analyzed mutation and expression status of human epidermal growth factor receptor 2 (Her2) in head and neck squamous cell carcinoma (HNSCC) using single strand conformation polymorphism (SSCP) mutation analysis and immunohistochemistry (IHC). Mutations were absent in all 85 cases. Out of 57 cases available for IHC, Her2 protein expression was negative (0) in 40 tumors (70%). Seventeen tumors (29.8%) expressed Her2, among these 13 tumors (22.8%) showed a weak (+1) expression and 4 (7%) showed a moderate expression (+2), none showed a strong (+3) expression. There was not a significant association between expression and any of the patients' clinical variables or prognosis. Our results suggest that Her2 may not be useful as a molecular target in HNSCC.
20
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text
Leah N. Klapper, Stefanie Glathe, Nora Vaisman et al. · Proceedings of the National Academy of Sciences · 1999 · 446 citations
Kaisa Erjala, Maria Sundvall, Teemu T. Junttila et al. · Clinical Cancer Research · 2006 · 265 citations · Full text
Medicine, Oncology, Pharmacology +17